Sabby Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Sabby Management’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,705	Closed	-$37.3K	–	34
2025 Q3	$37.3K	Buy	8,705 +4,610	+113%	+$27.8K	0.04%	35
2025 Q2	$41.8K	Sell	4,095 -98,132	-96%	-$790K	0.08%	38
2025 Q1	$797K	Buy	+102,227	New	+$1.38M	2.35%	12

Other funds holding ACXP

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return

Sabby Management's ACXP Position: Q4 2025 in Review

Sabby Management sold out of Acurx Pharmaceuticals (ACXP) in Q4 2025, closing a stake of 8,705 shares — an estimated $37.3K sold.

Sabby Management first reported a position in ACXP in Q1 2025 and held it in 3 quarters. The position peaked at $797K in Q1 2025. 18 funds tracked by Wall St. Rank hold ACXP as of Q4 2025.

Sabby Management reported no remaining Acurx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Sabby Management sold 8,705 Acurx Pharmaceuticals shares in Q4 2025, an estimated $37.3K.
Sabby Management first reported a position in Acurx Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Sabby Management's Acurx Pharmaceuticals position peaked at $797K in Q1 2025.
18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q4 2025.

Based on Sabby Management's 13F filing for Q4 2025, filed 17 Feb 2026.